OTC and hyperinsulinemic hypoglycemia, familial, 4: Through investigations in a splicing-defective mouse model of ornithine transcarbamylase deficiency, we provided the early proof-of-principle that an exon specific U1snRNA variant (U1O3) can be exploited in vivo to rescue OTC expression impaired by a splicing defect.